Carglumic acid

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
Carglumic acid
Generic name
CARGLUMIC ACID
Manufacturer
Burel Pharmaceuticals, LLC
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
2aee4281-402b-4cd6-9e6a-08945262e1a1
SPL ID
28393de7-fa10-4e7d-919e-4d0b19c888a1
Version
2
Effective date
2024-03-19
Source export date
2026-09-28
Source partition
11
Source file
https://download.open.fda.gov/drug/label/drug-label-0011-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-09-28/aa96b5a2be6b394393acd0090f6948bdf99e0e8e00666f81608929c8fa83db77/drug-label-0011-of-0014.json.zip
Source manifest SHA-256
cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
Import run
20260929T050834Z
Imported at
2026-09-29 06:15:06
Harmonized routes table
Harmonized routes
ORAL

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 2 matching rows.

adverse reactions

6 ADVERSE REACTIONS NAGS deficiency : Most common adverse reactions (≥13%) are vomiting, abdominal pain, pyrexia, tonsillitis, anemia, diarrhea, ear infection, infections, nasopharyngitis, hemoglobin decreased, and headache. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Navinta LLC at 1-609-883-1135, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Acute and Chronic Hyperammonemia due to NAGS Deficiency In a retrospective case series of 23 NAGS deficiency patients treated with Carglumic acid tablets for oral suspension, 17 of the 23 patients reported an adverse reaction. The most common adverse reactions (occurring in ≥ 13% of patients) were vomiting, abdominal pain, pyrexia, tonsillitis, anemia, diarrhea, ear infection, infections, nasopharyngitis, hemoglobin decreased, and headache. Table 1 summarizes adverse reactions occurring in 2 or more patients treated with carglumic acid tablets for oral suspension. Table 1: Adverse Reactions Reported in ≥ 2 Patients with NAGS deficiency Treated with Carglumic Acid Tablets for Oral Suspension in the Retrospective Case Series Adverse Reaction Number of Patients (N) (%) Vomiting 6 (26) Abdominal pain 4 (17) Pyrexia 4 (17) Tonsillitis 4 (17) Anemia 3 (13) Diarrhea 3 (13) Ear infection 3 (13) Infections 3 (13) Nasopharyngitis 3 (13) Hemoglobin decreased 3 (13) Headache 3 (13) Dysgeusia 2 (9) Asthenia 2 (9) Hyperhidrosis 2 (9) Influenza 2 (9) Pneumonia 2 (9) Weight decreased 2 (9) Anorexia 2 (9) Somnolence 2 (9) Rash 2 (9) 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of Carglumic acid tablets for oral suspension. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or to establish a causal relationship to drug exposure. Psychiatric disorders : mania Skin and subcutaneous tissue disorders : pruritus, rash including rash erythematous, rash maculopapular, rash pustular

adverse reactions table

<table ID="ID176" width="100%" styleCode="Noautorules"><caption> Table 1: Adverse Reactions Reported in &#x2265; 2 Patients with NAGS deficiency Treated with Carglumic Acid Tablets for Oral Suspension in the Retrospective Case Series </caption><col width="62%"/><col width="37%"/><tbody><tr><td valign="top" styleCode="Lrule Toprule Botrule Rrule" align="left"><content styleCode="bold"> Adverse Reaction</content> </td><td valign="top" styleCode=" Toprule Botrule Rrule" align="center"><content styleCode="bold"> Number of Patients (N) (%)</content> </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Vomiting </td><td styleCode=" Botrule Rrule" align="center"> 6 (26) </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Abdominal pain </td><td styleCode=" Botrule Rrule" align="center"> 4 (17) </td></tr><tr><td valign="top" styleCode=" Lrule Rrule" align="left"> Pyrexia </td><td styleCode=" Rrule" align="center"> 4 (17) </td></tr><tr><td valign="top" styleCode="Lrule Toprule Botrule Rrule" align="left"> Tonsillitis </td><td styleCode=" Toprule Botrule Rrule" align="center"> 4 (17) </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Anemia </td><td styleCode=" Botrule Rrule" align="center"> 3 (13) </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Diarrhea </td><td styleCode=" Botrule Rrule" align="center"> 3 (13) </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Ear infection </td><td styleCode=" Botrule Rrule" align="center"> 3 (13) </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Infections </td><td styleCode=" Botrule Rrule" align="center"> 3 (13) </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Nasopharyngitis </td><td styleCode=" Botrule Rrule" align="center"> 3 (13) </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Hemoglobin decreased </td><td styleCode=" Botrule Rrule" align="center"> 3 (13) </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Headache </td><td styleCode=" Botrule Rrule" align="center"> 3 (13) </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Dysgeusia </td><td styleCode=" Botrule Rrule" align="center"> 2 (9) </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Asthenia </td><td styleCode=" Botrule Rrule" align="center"> 2 (9) </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Hyperhidrosis </td><td styleCode=" Botrule Rrule" align="center"> 2 (9) </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Influenza </td><td styleCode=" Botrule Rrule" align="center"> 2 (9) </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Pneumonia </td><td styleCode=" Botrule Rrule" align="center"> 2 (9) </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Weight decreased </td><td styleCode=" Botrule Rrule" align="center"> 2 (9) </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Anorexia </td><td styleCode=" Botrule Rrule" align="center"> 2 (9) </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Somnolence </td><td styleCode=" Botrule Rrule" align="center"> 2 (9) </td></tr><tr><td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Rash </td><td styleCode=" Botrule Rrule" align="center"> 2 (9) </td></tr></tbody></table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.